journal article·2025-05-14

A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy

Guanru Wang, Hao Guo, Mengxin Wei, Ying Wang, Zengcai Jin, Jing Zhou, Jun He, Yaping Li

Nano Letters· Volume 25· Issue 19
Publisher page

Abstract

Chemotherapy for glioblastoma (GBM) has not achieved the desired outcome due to inefficient blood–brain barrier (BBB) penetration and limited tumor-specific drug accumulation. Strategies that employ bioinspired nanoparticles to enhance targeted drug accumulation can help improve therapeutic efficacy. In this work, a novel nanoparticle, PCM@TMA-lip, exhibiting hybrid-targeting capabilities, is presented, with an engineered cell membrane coated on a lipid core. The membrane modified with a biologically derived peptide enables PCM@TMA-lip to evade immune clearance and enable precise tumor targeting. The lipid core with docosahexaenoic acid (DHA)-conjugated Temozolomide (TMZ) enhances FABP7-mediated uptake, promotes lysosomal escape via lipid peroxidation, and reduces tumor migration and drug resistance. In vitro, PCM@TMA-lip inhibited tumor cell malignancy and suppressed the growth of 3D spheroids. In vivo, it suppressed tumor progression, reduced Ki67 + proliferation, increased TUNEL + apoptosis, and prolonged survival in GBM-bearing mice, highlighting its potential as an effective strategy to improve GBM chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, P.R. China

State Key Laboratory of Drug Research & Center of Pharmaceutics

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Department of Anesthesiology

Shanxi Provincial People’s Hospital

School of Chinese Materia Medical Nanjing University of Chinese Medicine

Department of Oncology

Shanxi Province Academy of Traditional Chinese Medicine, Shanxi Province Hospital of Traditional Chinese Medicine

Yantai Key Laboratory of Nanomedicine & Advanced Preparations

Yantai Institute of Materia Medica

Shandong Laboratory of Yantai Drug Discovery

Bohai Rim Advanced Research Institute for Drug Discovery

Funding

National Key Research and Development Program of China · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Special Fund for Science and Technology Innovation Teams of Shanxi Province · Special Fund for Science and Technology Innovation Teams of the Administration of TCM of Shanxi Province · Shandong Laboratory Program

References (43)

Show source-provided references
1. 10.1093/neuonc/noad04410.1093/neuonc/noad044 ↗
2. 10.1016/j.drudis.2019.03.00810.1016/j.drudis.2019.03.008 ↗
3. 10.1093/brain/awac45010.1093/brain/awac450 ↗
4. 10.1039/D2BM01996E10.1039/D2BM01996E ↗
5. 10.3390/biomedicines903032410.3390/biomedicines9030324 ↗
6. 10.1093/neuonc/noab00310.1093/neuonc/noab003 ↗
7. 10.20517/cdr.2019.6410.20517/cdr.2019.64 ↗
8. 10.1158/1078-0432.CCR-03-080710.1158/1078-0432.CCR-03-0807 ↗
9. 10.1021/acsnano.3c0337810.1021/acsnano.3c03378 ↗
10. 10.1002/adhm.20240310810.1002/adhm.202403108 ↗
11. 10.3390/cancers1302019510.3390/cancers13020195 ↗
12. 10.1007/s13346-022-01149-y10.1007/s13346-022-01149-y ↗
13. 10.1002/adma.20170430710.1002/adma.201704307 ↗
14. 10.1016/j.jconrel.2021.08.02110.1016/j.jconrel.2021.08.021 ↗
15. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
16. 10.1016/j.jconrel.2023.11.04610.1016/j.jconrel.2023.11.046 ↗
17. 10.1016/j.mtcomm.2022.10428910.1016/j.mtcomm.2022.104289 ↗
18. 10.1021/acsnano.9b0999110.1021/acsnano.9b09991 ↗
19. 10.1016/j.ejpb.2019.06.00410.1016/j.ejpb.2019.06.004 ↗
20. 10.2174/092986652666619022812284910.2174/0929866526666190228122849 ↗
21. 10.1021/ja010452r10.1021/ja010452r ↗
22. 10.1186/s12951-021-01097-810.1186/s12951-021-01097-8 ↗
23. 10.1016/S0896-6273(01)00234-310.1016/S0896-6273(01)00234-3 ↗
24. 10.1172/JCI20011399210.1172/JCI200113992 ↗
25. 10.1016/j.str.2010.05.01710.1016/j.str.2010.05.017 ↗
26. 10.1016/j.jconrel.2023.05.01210.1016/j.jconrel.2023.05.012 ↗
27. 10.1080/10717544.2016.123359310.1080/10717544.2016.1233593 ↗
28. 10.3390/nu1308266410.3390/nu13082664 ↗
29. 10.1021/acs.jproteome.5b0007610.1021/acs.jproteome.5b00076 ↗
30. 10.1016/j.bbagen.2016.07.00410.1016/j.bbagen.2016.07.004 ↗
31. 10.3390/biomedicines1103077910.3390/biomedicines11030779 ↗
32. 10.14712/fb202206802005910.14712/fb2022068020059 ↗
33. 10.1039/D1NR02128A10.1039/D1NR02128A ↗
34. 10.2174/156720181366615122810464310.2174/1567201813666151228104643 ↗
35. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
36. 10.1021/acs.bioconjchem.9b0013610.1021/acs.bioconjchem.9b00136 ↗
37. 10.1016/j.jlr.2022.10024810.1016/j.jlr.2022.100248 ↗
38. 10.1016/j.biomaterials.2013.03.00810.1016/j.biomaterials.2013.03.008 ↗
39. 10.1093/toxsci/kfac05810.1093/toxsci/kfac058 ↗
40. 10.1038/s41467-019-12470-510.1038/s41467-019-12470-5 ↗
41. 10.1016/j.jcis.2021.08.14810.1016/j.jcis.2021.08.148 ↗
42. 10.1016/j.actbio.2023.01.00410.1016/j.actbio.2023.01.004 ↗
43. 10.1039/C9TB00685K10.1039/C9TB00685K ↗